Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind (With Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients With Active Disease Receiving Background Methotrexate or Sulphasalazine

NCT00520572 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00520572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00520572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind (With Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients With Active Disease Receiving Background Methotrexate or Sulphasalazine
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
March 31, 2009
Enrollment
385 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis